The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
Abstract Background To provide real‐world outcomes for the combination of etoposide and platinum as a first‐line treatment for advanced thymic neuroendocrine neoplasms (TNENs). Methods Retrospective analysis was performed on patients with advanced TNENs confirmed by pathology who received etoposide...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6245 |
| _version_ | 1827386703888777216 |
|---|---|
| author | Yelan Guan Qifeng Yao Yue Hao Xiaohong Zeng Wenxian Wang Xiadong Gu Jing Xiang Yan Sun Zhengbo Song |
| author_facet | Yelan Guan Qifeng Yao Yue Hao Xiaohong Zeng Wenxian Wang Xiadong Gu Jing Xiang Yan Sun Zhengbo Song |
| author_sort | Yelan Guan |
| collection | DOAJ |
| description | Abstract Background To provide real‐world outcomes for the combination of etoposide and platinum as a first‐line treatment for advanced thymic neuroendocrine neoplasms (TNENs). Methods Retrospective analysis was performed on patients with advanced TNENs confirmed by pathology who received etoposide combined with platinum as a first‐line chemotherapy in our institution between 2010 and 2022. Results A total of 16 patients were included in this study. Twelve patients (75%) received etoposide combined with cisplatin, and four patients (25%) received etoposide combined with carboplatin. Efficacy was evaluated in all patients, with an objective response rate of 31.3%. One patient achieved a complete response, four achieved a partial response, and in eight patients the disease remained stable; the disease control rate was 81.3%. The median progression‐free survival (PFS) was 7.2 months with a 95% confidence interval (CI) of 2.1–12.3 months. The median overall survival (OS) was 50.4 months with a 95% CI of 32.1–68.8 months. No significant difference in efficacy was observed between the treatment groups with regards to PFS (p = 0.095) and OS (p = 0.061). Treatment‐related adverse events were observed in all 12 patients when evaluated for toxicity, manifesting as hematologic toxicity. Grade 3–4 bone marrow suppression occurred in six patients (50%). No treatment‐related deaths were recorded. Conclusion This retrospective analysis, conducted in a real‐life setting, suggests that the combination of etoposide and platinum has a promising anti‐tumor activity in advanced TNENs, with a clinically significant overall response rate. |
| first_indexed | 2024-03-08T15:50:23Z |
| format | Article |
| id | doaj.art-15976403f132470189297564dbb62710 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-08T15:50:23Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-15976403f132470189297564dbb627102024-01-09T05:41:08ZengWileyCancer Medicine2045-76342023-08-011215160111601810.1002/cam4.6245The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysisYelan Guan0Qifeng Yao1Yue Hao2Xiaohong Zeng3Wenxian Wang4Xiadong Gu5Jing Xiang6Yan Sun7Zhengbo Song8Department of Phase I Clinical Trial Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang ChinaPostgraduate training base Alliance of Wenzhou Medical University Zhejiang Cancer Hospital Hangzhou Zhejiang ChinaDepartment of Phase I Clinical Trial Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang ChinaDepartment of Phase I Clinical Trial Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang ChinaDepartment of Thoracic Medical Oncology Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang ChinaThe Second Clinical Medical College of Zhejiang Chinese Medical University Hangzhou Zhejiang ChinaDepartment of Phase I Clinical Trial Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang ChinaDepartment of Phase I Clinical Trial Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang ChinaDepartment of Phase I Clinical Trial Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou Zhejiang ChinaAbstract Background To provide real‐world outcomes for the combination of etoposide and platinum as a first‐line treatment for advanced thymic neuroendocrine neoplasms (TNENs). Methods Retrospective analysis was performed on patients with advanced TNENs confirmed by pathology who received etoposide combined with platinum as a first‐line chemotherapy in our institution between 2010 and 2022. Results A total of 16 patients were included in this study. Twelve patients (75%) received etoposide combined with cisplatin, and four patients (25%) received etoposide combined with carboplatin. Efficacy was evaluated in all patients, with an objective response rate of 31.3%. One patient achieved a complete response, four achieved a partial response, and in eight patients the disease remained stable; the disease control rate was 81.3%. The median progression‐free survival (PFS) was 7.2 months with a 95% confidence interval (CI) of 2.1–12.3 months. The median overall survival (OS) was 50.4 months with a 95% CI of 32.1–68.8 months. No significant difference in efficacy was observed between the treatment groups with regards to PFS (p = 0.095) and OS (p = 0.061). Treatment‐related adverse events were observed in all 12 patients when evaluated for toxicity, manifesting as hematologic toxicity. Grade 3–4 bone marrow suppression occurred in six patients (50%). No treatment‐related deaths were recorded. Conclusion This retrospective analysis, conducted in a real‐life setting, suggests that the combination of etoposide and platinum has a promising anti‐tumor activity in advanced TNENs, with a clinically significant overall response rate.https://doi.org/10.1002/cam4.6245efficacyetoposideplatinumsafetythymic neuroendocrine neoplasms |
| spellingShingle | Yelan Guan Qifeng Yao Yue Hao Xiaohong Zeng Wenxian Wang Xiadong Gu Jing Xiang Yan Sun Zhengbo Song The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis Cancer Medicine efficacy etoposide platinum safety thymic neuroendocrine neoplasms |
| title | The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis |
| title_full | The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis |
| title_fullStr | The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis |
| title_full_unstemmed | The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis |
| title_short | The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis |
| title_sort | combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms a retrospective analysis |
| topic | efficacy etoposide platinum safety thymic neuroendocrine neoplasms |
| url | https://doi.org/10.1002/cam4.6245 |
| work_keys_str_mv | AT yelanguan thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT qifengyao thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT yuehao thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT xiaohongzeng thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT wenxianwang thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT xiadonggu thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT jingxiang thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT yansun thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT zhengbosong thecombinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT yelanguan combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT qifengyao combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT yuehao combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT xiaohongzeng combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT wenxianwang combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT xiadonggu combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT jingxiang combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT yansun combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis AT zhengbosong combinationofetoposideandplatinumforthetreatmentofthymicneuroendocrineneoplasmsaretrospectiveanalysis |